Innosweet®: An Engineered D-Pinitol Functional Sweetener — Human Clinical Data

This human clinical study, published in Nutrients, characterized the pharmacokinetics and endocrine effects of D-Pinitol, evaluated both as a purified compound and as delivered through Innosweet® — a chromatographically refined, composition-controlled matrix of balanced sugars and D-Pinitol, not a crude carob extract. The research reported that Innosweet® delivers D-Pinitol with efficient oral absorption, a prolonged absorption phase, and an extended half-life exceeding five hours.

Delivered through Innosweet®, D-Pinitol maintained systemic bioavailability with a moderate, more controlled plasma exposure profile. Innosweet® was associated with a lower insulin response without altering blood glucose levels, alongside increased glucagon and ghrelin concentrations — consistent with a balanced endocrine response rather than a glycemic spike.

These findings position Innosweet® as an engineered functional sweetener matrix — a defined, standardized composition designed to deliver sweetness together with support for healthy glucose and insulin balance. Unlike crude carob syrups, Innosweet® pairs a controlled sugar–D-Pinitol composition with human clinical characterization, making it a differentiated, science-backed alternative to conventional sugars and to commodity extracts for weight management, metabolic wellness, and functional nutrition applications.

This study evaluated pharmacokinetic and endocrine responses in healthy human volunteers. These statements have not been evaluated by the Food and Drug Administration. Innosweet® is an ingredient and is not intended to diagnose, treat, cure, or prevent any disease.